<DOC>
	<DOCNO>NCT02639338</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability treatment sofosbuvir/velpatasvir/voxilaprevir ( SOF/VEL/VOX ) fixed-dose combination ( FDC ) 8 week treatment sofosbuvir/velpatasvir ( SOF/VEL ) FDC 12 week adults chronic genotype 3 hepatitis C virus ( HCV ) infection cirrhosis previously receive treatment direct-acting antiviral ( DAA ) therapy .</brief_summary>
	<brief_title>Safety Efficacy SOF/VEL/VOX FDC 8 Weeks SOF/VEL 12 Weeks Adults Chronic Genotype 3 HCV Infection Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen Chronic genotype 3 HCV infection ( ≥ 6 month ) Presence cirrhosis HCV treatment naive treatment experience interferon ( IFN ) base regimen Use protocol specify method contraception Key Current prior history clinically significant illness may interfere participation study Screening ECG clinically significant abnormality Laboratory parameter outside acceptable range screen Pregnant nursing female Chronic liver disease cause HCV Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic</keyword>
</DOC>